# OnCo record wjb001 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/wjb001/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "wjb001" ;
  schema:name "WJB001"@en ;
  schema:alternateName "Wee1 inhibitor+ Taxol/Abraxane"@en, "Wee1 inhibitor+ PARAPLATIN/Aqupla"@en, "Wee1 inhibitor+ PARAPLATIN+Taxol"@en, "Wee1 inhibitor+ Zejula"@en ;
  schema:description "WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer."@en ;
  schema:url <https://onco.cc/drugs/wjb001/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=WJB001> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest", "registry-only" ;
  onco:modality "Small-molecule inhibitor" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:companies <https://onco.cc/companies/wigen-biomedicine-technology-shanghai/> ;
  onco:trials <https://onco.cc/trials/nct05773820/>, <https://onco.cc/trials/nct06953323/>, <https://onco.cc/trials/nct06953323/>, <https://onco.cc/trials/nct06953323/>, <https://onco.cc/trials/nct06953323/>, <https://onco.cc/trials/nct06953323/>, <https://onco.cc/trials/nct06953323/>, <https://onco.cc/trials/nct06953323/> .